Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2017. The document serves as a transaction notification regarding shareholding changes by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price | Volume |
|---|---|---|---|
| January 12, 2017 | Ordinary Shares (GBP) | £15.7075 | Various (195.631 to 489.079) |
| January 12, 2017 | American Depositary Shares (USD) | $38.9750 | 307.510 |
Material Changes
The filing reports an increase in notional interest in company shares for six executives. These changes resulted from the automatic re-investment of dividends paid on January 12, 2017, under the Company's Deferred Investment Award Programme. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a routine regulatory disclosure of insider shareholding updates.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic dividend re-investments, not open market purchases or sales by the executives.
- Executives Involved: Ms E Walmsley (CEO Designate), Mr R G Connor, Mr S A Hussain, Mr B McNamara, Mr D S Redfern, Ms C Thomas, and Dr P J T Vallance.
- Share Price: The Ordinary Share price was £15.7075 and the ADS price was $38.9750 on the transaction date.
- Scope: This filing does not contain financial performance data; investors should refer to the company's Form 20-F or quarterly reports for financial metrics.